CareDx, Inc logo

CareDx, Inc

CDNA

NASDAQHealthcareMedical - Diagnostics & Research

前收盘价

US$48.61

+US$1.62 · +3.45%

8月21日 16:00 ET

盘前

US$48.75

+US$0.14 · +0.29%

8月24日 4:49 ET

CDNA公司概览

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

GoAI评分

Sell

Trim exposure — unfavorable risk-reward

估值

8

Overpriced

动量

70

Gaining

情绪

57

Mixed

风险韧性

44

Elevated Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考,并非投资建议。

公司概况

公司网站

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

行业
Medical - Diagnostics & Research
部门
Healthcare
总部
US
首席执行官
John Walter Hanna Jr.
上市以来
2014年7月17日
雇员
763

市场位置

日内区间

当前US$48.61,

52周区间

当前US$48.61,

开盘价
US$46.99
前收盘价
US$46.99
成交量
116.05万
1.19× 平均值
平均成交量
97.88万
日均成交量
市值
25.15亿 USD
贝塔
2.42
市场参考 1
50天平均值
US$35.671
高于平均水平+36.27%
200天平均值
US$23.3534
高于平均水平+108.15%

财务数据

财务快照

最近十二个月

估值与收益率

企业价值
9.65亿 USD
市盈率(TTM)
22.59×
市净率(TTM)
5.88×
市销率(TTM)
5.49×
EV/EBITDA
-207.24×
盈利收益率
-2.13%
自由现金流收益率
3.60%
股息率
0.00%

盈利能力和效率

毛利率
70.58%
营业利润率
-0.92%
净利润率
24.23%
净资产收益率
-7.05%
资产收益率
-5.17%
投入资本回报率
-7.60%

财务健康

负债权益比
0.05×
流动比率
2.86×

财报历史与展望

最新财年每股收益
-0.4
2025财年 · 同比-143.01%
最新财年收入
3.8亿 USD
2025财年 · 同比+13.79%
下一财年每股收益共识
1.21
2026财年 · 4位分析师
下一财年收入共识
4.95亿 USD
2026财年 · 5位分析师

年度每股收益趋势

已公布业绩及可用的市场共识预期。

已公布市场共识预期
年度每股收益趋势3.090.68-1.73-4.1421财年22财年23财年24财年25财年26财年27财年28财年

年度营收趋势

已公布业绩及可用的市场共识预期。

已公布市场共识预期
年度营收趋势5.53亿4.54亿3.55亿2.56亿21财年22财年23财年24财年25财年26财年27财年

分析师评级

第三方分析师预期可能变化,并非 GoAI 建议。

评级分布

13项评级
强力买入00%
买入1077%
持有323%
卖出00%
强力卖出00%

CDNA 消息

CDNA同业公司

持有CDNA的ETF

报告持有此股票敞口的交易所交易基金。

继续GoAI的研究

在 GoAI 中研究CDNA

research.disclaimer